Gastrointestinal Cancer
Conditions
Keywords
Gastrointestinal Cancer, Propranolol
Brief summary
To research the effect of propranolol on the proliferation and apoptosis of gastrointestinal cancer.
Interventions
DRUGPropranolol
0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
Sponsors
Central South University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. patients with gastric adenocarcinoma and colon cancer were diagnosed by histology and cytology, and there was a clear metastasis (TxNxM0); 2. without any prior treatment (including surgery or radiotherapy and chemotherapy) in the I-III period, no distant metastasis, suitable for patients with surgical resection of the tumor. 3. the age range of the patients is 18-60; 4. systolic pressure 100-140mmHg; heart rate \>60bpm; 5. the patient's survival time should be longer than 3 months; 6. without previous cardiovascular and cerebrovascular diseases, the atrioventricular block was excluded by the 24 hour dynamic electrocardiogram; 7. ECOG score of 2 (that means the patient's bed time is less than 50%); Karnofsky score of 60% (that means patients have the basic activities and self-care ability); 8. the basic biochemical examination results of patients with normal: white blood cell 3000/ul; neutrophil 1500/ul 100000/ul; platelet count; total bilirubin \< 1.5 x ULN; AST / ALT 2.5 x ULN without liver metastasis; \< 5 x ULN liver metastasis; creatinine clearance rate of 1.5 x ULN; 9. have the ability to understand and sign informed consent.
Exclusion criteria
1. pregnant or lactating women; 2. patients with severe heart disease, kidney disease, metabolic disorders, bronchial asthma, cardiogenic shock, heart block (II-III degree atrioventricular block), or severe acute heart failure, sinus bradycardia. 3. patients with epilepsy or psychotropic drugs and sedatives; 4. patients with brain metastasis and bone marrow metastasis; 5. participants in clinical trials of other drugs within 4 weeks; 6. patients with a history of anaphylaxis with propranolol; 7. patients treated with trastuzumab; 8. patients with or reactive immunodeficiency, such as those with HIV infection; 9. the uncontrollable situation in the group during the period (but not limited to these cases): according to the experimental scheme of medication, severe infection, due to mental illness or other social factors lead to the compliance requirements of patients; 10. patients with atrioventricular block should be discontinued immediately and quit; 11. the researchers believe there may be any increase in the risk of the subject or any interference with clinical trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor size will be measured. | Our experiment completed after patients took medicine for one week. | We used CT and Ki67 to confirm that the drug's affection. |
Countries
China
Contacts
Primary ContactYijing He
Outcome results
None listed